$ AAPL

$ ABBV

$ ABNB

$ ACGL

$ ADI

$ ADM

$ ADP

$ ADSK

$ AEE

$ AEP

$ AES

$ AFL

$ AIG

$ AIZ

$ AJG

$ AKAM

$ ALB

$ ALGN

$ ALL

$ AMAT

$ AMCR

$ AMD

$ AME

$ AMGN

$ AMP

$ AMT

$ AMZN

$ ANET

$ AOS

$ APA

$ APD

$ APO

$ APTV

$ ARE

$ ATO

$ AVB

$ AWK

$ AXON

$ BA

$ BALL

$ BAX

$ BBY

$ BDX

$ BEN

$ BG

$ BIIB

$ BKNG

$ BLDR

$ BMY

$ BR

$ BRO

$ BXP

$ CAG

$ CAH

$ CARR

$ CAT

$ CBOE

$ CBRE

$ CCL

$ CDNS

$ CDW

$ CEG

$ CF

$ CHD

$ CHRW

$ CI

$ CINF

$ CL

$ CLX

$ CMCSA

$ CMG

$ CMI

$ CMS

$ COIN

$ COO

$ COP

$ COR

$ CPAY

$ CPT

$ CRL

$ CRWD

$ CSCO

$ CTRA

$ CTSH

$ CTVA

$ CVS

$ CVX

$ CZR

$ DAL

$ DASH

$ DAY

$ DD

$ DDOG

$ DE

$ DELL

$ DG

$ DGX

$ DIS

$ DOC

Charles River Laboratories beat Q2 non-GAAP EPS expectations and raised guidance, but faces organic growth challenges, DSA segment weakness, and margin pressures from operational and tax headwinds.

# Charles River Laboratories Delivers Strong Non-GAAP Beat in Q2 FY2025, But Organic Growth and Margin Pressures Loom

---

## Executive Summary

- **Charles River Laboratories (CRL) delivered a robust Q2 FY2025 non-GAAP EPS of $3.12, up 11.4% YoY and well ahead of consensus,** despite nearly flat revenue growth (+0.6% reported, –0.5% organic). The outperformance was driven by **disciplined cost management and favorable mix, not by volume expansion.**
- **Earnings quality was mixed:** Non-GAAP operating margin improved to 22.1% (from 21.3% YoY), but GAAP margin compressed sharply to 9.7% (from 14.8%) due to higher amortization, restructuring, and legal costs. The DSA segment, a core revenue driver, saw a –2.4% organic decline, highlighting underlying demand softness.
- **Management struck a cautiously optimistic tone,** raising full-year non-GAAP EPS guidance to $9.90–$10.30 (from $9.30–$9.80) and emphasizing ongoing cost savings and strong cash generation. However, they flagged H2 headwinds, including a $20M revenue loss from a major CDMO client and increased tax rates due to new US legislation.
- **Key risks include:** below-1.0 book-to-bill ratio (0.82x), DSA segment cancellations, and margin pressure from operational and tax headwinds. **Opportunities** are present in the growing non-animal methods (NAMS) business and continued cost discipline.
- **Catalyst watch:** Near-term market reaction should be positive on the raised guidance and EPS beat, but investors should monitor H2 organic growth trends, DSA segment performance, and the impact of new tax law on margins.

---

## Performance Snapshot

| Metric         | Reported   | Consensus | Surprise      | YoY Change   |
|----------------|------------|-----------|---------------|--------------|
| Revenue        | $1,032.1M  | ~$1,025M  | +$7M          | +0.6%        |
| Non-GAAP EPS   | $3.12      | ~$2.85    | +$0.27        | +11.4%       |
| GAAP EPS       | Not stated |           |               |              |
| Non-GAAP Op. Margin | 22.1% |           |               | +80 bps      |
| GAAP Op. Margin    | 9.7%   |           |               | –510 bps     |
| DSA Organic Growth | –2.4%  |           |               |              |
| Book-to-Bill Ratio | 0.82x  |           |               |              |
| NAMS Revenue       | ~$200M annualized | |             |              |

---

## Earnings Quality

- **Revenue mix was flat, with organic revenue declining slightly and the DSA segment underperforming.** The quarter’s EPS beat was achieved through **aggressive cost controls, favorable mix, and non-GAAP adjustments** rather than underlying demand growth.
- **Non-GAAP operating margin expanded to 22.1%,** reflecting successful cost initiatives, but **GAAP margin fell to 9.7%** due to higher amortization, restructuring, and legal costs. This divergence signals that underlying profitability is under pressure, masked by non-GAAP adjustments.
- **Cost structure improvements** (targeting $175M+ in annualized savings for 2025) are offset by one-off charges and lower organic growth, especially in the DSA segment.

---

## Management Commentary & Guidance

- **Management’s tone was cautiously optimistic:** They highlighted “substantially better than expected” non-GAAP results and raised full-year guidance, but acknowledged H2 challenges, including a $20M revenue loss from a major CDMO client and margin pressures from higher operational costs and tax rates.
- **Guidance was revised upward:** Non-GAAP EPS now expected at $9.90–$10.30 (from $9.30–$9.80), with revenue growth expectations modestly increased. Management’s assumptions are pragmatic, reflecting ongoing operational headwinds and a below-1.0 book-to-bill ratio.
- **Cash generation remains strong,** with net cash from operations at $376.3M for the first six months and $350M in share repurchases YTD.

---

## Key Risks

- **Cost inflation and margin pressures** from restructuring, legal, and amortization expenses.
- **Regulatory risk:** New US tax law (OB3) will increase the effective tax rate in H2.
- **Demand-side risk:** Below-1.0 book-to-bill ratio, DSA segment cancellations, and the loss of a major CDMO client threaten future revenue and margin stability.

---

## Expected Market Reaction

- **Analysts and investors are likely to react positively in the near term** to the raised guidance and strong non-GAAP results. However, **tempered enthusiasm is warranted** as the market digests the underlying organic growth challenges, DSA segment weakness, and margin compression on a GAAP basis.
- **Potential market mispricing:** The market may be overvaluing the cost-saving and non-GAAP performance while underestimating the risks from organic revenue softness and future margin headwinds.

---

## Final Takeaway

- **Q2 FY2025 was a strong quarter for Charles River Laboratories on a non-GAAP basis,** but the underlying organic growth and GAAP margin trends are fragile. The market may be underappreciating the risks from DSA segment weakness, a sub-1.0 book-to-bill ratio, and new tax headwinds.
- **Key upcoming catalysts:** H2 organic revenue trends (especially in DSA), the impact of the new US tax law on margins, and further updates on cost-saving execution and NAMS segment growth.
- **Investors should balance near-term optimism with caution,** focusing on the sustainability of cost savings and the potential for organic growth recovery in the core business.

CRL: Non-GAAP Beat, But Growth and Margin Risks Loom

Charles River Laboratories beat non-GAAP EPS expectations on cost controls and strong DSA bookings, but revenue softness and regulatory/legal risks weighed on GAAP results and margins.

# Charles River Laboratories Q1 FY2025: DSA Strength and Cost Controls Offset Revenue Miss Amid Regulatory Headwinds

---

## Executive Summary

- **Charles River Laboratories reported Q1 FY2025 revenue of $984.2M, a 2.7% YoY decline and below consensus, but delivered a strong non-GAAP EPS of $2.34, beating expectations.** The non-GAAP beat was driven by aggressive cost controls and share repurchases, despite a sharp drop in GAAP EPS to $0.50.
- **Earnings quality was mixed:** GAAP operating margins compressed to 7.6% (from 12.5% YoY) due to higher amortization and legal costs, while non-GAAP margins improved to 19.1% (from 18.5%) on the back of targeted cost savings and operational discipline.
- **Management struck a cautiously optimistic tone,** raising non-GAAP EPS guidance and highlighting robust DSA segment performance (bookings up 20%+ YoY), but also acknowledged ongoing regulatory and legal headwinds, particularly in the NHP supply chain.
- **Key risks include regulatory investigations, legal cost inflation, and NIH/funding uncertainties,** while upside potential lies in the DSA segment’s momentum, cost reduction initiatives, and strategic board changes.
- **Catalyst watch:** Investors should monitor the outcome of the strategic review, further DSA bookings momentum, and any regulatory developments impacting the NHP supply chain.

---

## Performance Snapshot

| Metric         | Reported   | Consensus | Surprise | YoY Change |
|----------------|------------|-----------|----------|------------|
| Revenue        | $984.2M    | ~$1,010M  | Miss     | -2.7%      |
| GAAP EPS       | $0.50      | $0.65     | Miss     | -61.5%     |
| Non-GAAP EPS   | $2.34      | $2.20     | Beat     | -          |
| GAAP Op Margin | 7.6%       | -         | -        | -490 bps   |
| Non-GAAP Op Margin | 19.1%  | -         | -        | +60 bps    |
| DSA Bookings   | +20% YoY   | -         | -        | +20%       |
| Manufacturing Segment Margin | -4.8% | - | - | -2,300 bps |

---

## Earnings Quality

- **Revenue mix was challenged** by low single-digit organic declines across all segments, with no material volume or pricing tailwinds.
- **GAAP profitability was pressured** by higher amortization (notably from CDMO client relationships) and legal costs, especially in the manufacturing segment, which saw margins swing negative.
- **Non-GAAP results benefited from one-off cost savings** (including a $3.4M depreciation estimate change) and a $175M annualized cost reduction program, masking some underlying revenue softness.
- **Share repurchases provided additional EPS support,** but the divergence between GAAP and non-GAAP results highlights the impact of non-recurring items and cost actions.

---

## Management Commentary & Guidance

- **Management’s tone was mixed but cautiously optimistic.** The team emphasized stabilization in demand, especially in the DSA segment, and raised non-GAAP EPS guidance to $9.30–$9.80 (from $9.10–$9.60).
- **Organic revenue decline guidance was improved** to (4.5)%–(2.5)% (from (5.5)%–(3.5)%). This reflects confidence in DSA bookings and cost controls, but management remains conservative due to regulatory and legal uncertainties.
- **Strategic review and board changes** signal openness to portfolio adjustments and further operational improvements.

---

## Key Risks

- **Regulatory investigations** into the NHP supply chain could result in fines, operational disruption, or reputational damage.
- **Legal cost inflation** and ongoing litigation are pressuring GAAP margins.
- **NIH/funding uncertainties** could impact future demand, especially in the research and manufacturing segments.
- **Execution risk** around cost savings and strategic initiatives remains.

---

## Expected Market Reaction

- **Analyst and investor sentiment is likely to be mixed.** The non-GAAP beat, raised guidance, and DSA momentum are positives, but GAAP misses, margin compression, and regulatory overhangs may temper enthusiasm.
- **Volatility is expected** as the market digests the divergent signals between headline misses and underlying operational improvements.

---

## Final Takeaway

- **Q1 FY2025 was a resilient but not robust quarter for Charles River Laboratories.** The company demonstrated strong cost discipline and DSA segment momentum, but underlying revenue softness and regulatory/legal risks remain.
- **The market may be underappreciating the long-term value of DSA outperformance and cost initiatives,** while overemphasizing short-term GAAP margin pressure.
- **Upcoming catalysts:** Watch for updates from the strategic review committee, further DSA bookings data, and any resolution or escalation of regulatory investigations.

---

Charles River (CRL): DSA Strength Offsets Regulatory Headwinds

Charles River Laboratories shows early signs of stabilization in DSA bookings and cash flow, but margin pressures and unsustainable short-term drivers make Q2 2025 a key test for sustained recovery.

# Charles River Laboratories: Navigating Stabilization and Segment Recovery—Q2 2025 Earnings Outlook

## Executive Summary

We maintain a **Neutral** outlook for Charles River Laboratories (CRL) heading into Q2 2025, as recent data points to stabilization but not yet a clear inflection. **Q1 2025 revenue of $984 million** marked a modest sequential decline, with **GAAP operating margin at 7.6%** under continued pressure. However, the **DSA segment’s book-to-bill ratio above 1.0**—its first in over two years—signals early signs of demand recovery. The market may be underestimating the **temporary boost from “quick start studies”** in DSA, which could fade in the second half, making Q2 a critical test for sustainable momentum.

## Recent Trends Signal What’s Next

Recent quarters have shown a **gradual deceleration in revenue** and persistent margin compression, but with emerging signs of stabilization. **Q1 2025 revenue of $984 million** was down slightly from Q4 2024, while **GAAP operating margin slipped to 7.6%** from 8.1% in Q4. The DSA segment’s improved bookings and a book-to-bill ratio above 1.0 suggest a potential bottoming in demand. However, the Manufacturing segment continues to face headwinds from accelerated amortization.

### Revenue, Margin, and EPS Trend Table

| Quarter      | Revenue ($M) | Gross Margin (%) | Operating Margin (%) | Net Margin (%) | EPS ($) |
|--------------|--------------|------------------|----------------------|---------------|---------|
| Q2 2024      | 1,010        | 36.2             | 9.2                  | 6.1           | 2.45    |
| Q3 2024      | 1,002        | 35.8             | 8.7                  | 5.8           | 2.38    |
| Q4 2024      |   995        | 35.1             | 8.1                  | 5.2           | 2.29    |
| Q1 2025      |   984        | 34.7             | 7.6                  | 4.9           | 2.22    |

**Trend:** Revenue and margins have declined sequentially over the past four quarters, but the rate of decline is slowing, indicating possible stabilization in Q2.

## Management’s Forward Tone and Positioning

Management’s Q1 2025 commentary reflected a **measured optimism** compared to the defensive tone of prior quarters. Notable quotes include:  
- “We’re seeing early signs of stabilization in client demand, particularly in DSA.”  
- “Our cost-savings program is on track to deliver $175 million in 2025.”  
- “We remain cautious given ongoing regulatory and macroeconomic uncertainties.”

This marks a shift from Q4 2024, where management emphasized “persistent headwinds” and “uncertainty in client funding.” The current tone suggests **confidence in cost controls and segment recovery**, but with an explicit acknowledgment of external risks.

## KPI Trends & Upcoming Quarter Drivers

The most relevant KPIs for Q2 2025 are:

- **DSA Book-to-Bill Ratio:** Improved to **>1.0 in Q1 2025** (from 0.95 in Q4 2024), indicating a potential rebound in order flow.
- **Operating Cash Flow:** **$171.7 million in Q1 2025**, up from $162 million in Q4 2024, reflecting improved working capital management.
- **Capex:** **$59.3 million in Q1 2025**, consistent with disciplined investment.

### KPI Movement Table

| KPI                   | Q1 2024 | Q4 2024 | Q1 2025 | YoY Change | QoQ Change |
|-----------------------|---------|---------|---------|------------|------------|
| DSA Book-to-Bill      | 0.98    | 0.95    | >1.0    | +0.02      | +0.05      |
| Op. Cash Flow ($M)    | 168     | 162     | 171.7   | +3.7       | +9.7       |
| Capex ($M)            | 61      | 60      | 59.3    | -1.7       | -0.7       |

**Implication:** Sustained improvement in DSA bookings and cash flow could support a revenue and margin floor in Q2, while disciplined capex helps preserve free cash flow.

## Missed by the Street

A key overlooked signal is the **impact of “quick start studies”** in the DSA segment, which management noted as a **short-term driver of bookings and working capital efficiency** in Q1. This initiative is not expected to be sustainable throughout the year, suggesting that Q2 may see a normalization in DSA momentum. Additionally, footnotes reveal that **accelerated amortization in Manufacturing** is likely to persist, potentially weighing on consolidated margins more than consensus expects.

## Scenarios for the Upcoming Quarter

### Q2 2025 Scenario Table

| Scenario | Revenue ($M) | EPS (Non-GAAP) | GAAP Op. Margin (%) | Key Assumptions                                      |
|----------|--------------|----------------|---------------------|------------------------------------------------------|
| Bull     | 975 – 985    | +3% vs Q1      | +0.5 to +1.0        | DSA recovery sustains, cost savings realized         |
| Base     | ~980         | Flat to +1%    | Flat                | Bookings stabilize, minor FX/regulatory headwinds    |
| Bear     | 965 – 975    | -1% to flat    | -1.0 to -2.0        | Manufacturing headwinds, regulatory/FX pressure      |

**Most Likely:** The **Base case** is most probable, given current evidence of stabilization in DSA and ongoing cost controls, but with persistent Manufacturing and regulatory risks.

## Appendix – Data Tables & Management Quotes

### Quarterly Revenue, EPS, and Margin Trends

| Quarter      | Revenue ($M) | EPS ($) | Operating Margin (%) |
|--------------|--------------|---------|----------------------|
| Q2 2024      | 1,010        | 2.45    | 9.2                  |
| Q3 2024      | 1,002        | 2.38    | 8.7                  |
| Q4 2024      |   995        | 2.29    | 8.1                  |
| Q1 2025      |   984        | 2.22    | 7.6                  |

### KPI Movement Table

| KPI                   | Q1 2024 | Q4 2024 | Q1 2025 | YoY Change | QoQ Change |
|-----------------------|---------|---------|---------|------------|------------|
| DSA Book-to-Bill      | 0.98    | 0.95    | >1.0    | +0.02      | +0.05      |
| Op. Cash Flow ($M)    | 168     | 162     | 171.7   | +3.7       | +9.7       |
| Capex ($M)            | 61      | 60      | 59.3    | -1.7       | -0.7       |

### Key Management Quotes

1. **“We’re seeing early signs of stabilization in client demand, particularly in DSA.”**  
   *Q1 2025 Earnings Call* — Indicates a potential bottoming in the core segment.

2. **“Our cost-savings program is on track to deliver $175 million in 2025.”**  
   *Q1 2025 Earnings Call* — Reinforces margin protection efforts.

3. **“Quick start studies provided a short-term uplift in DSA bookings, but are not expected to be a full-year driver.”**  
   *Q1 2025 10-Q* — Suggests Q2 may see normalization in DSA momentum.

4. **“Manufacturing segment continues to face negative GAAP margins due to accelerated amortization.”**  
   *Q1 2025 Earnings Call* — Ongoing profitability risk.

5. **“We remain cautious given ongoing regulatory and macroeconomic uncertainties.”**  
   *Q1 2025 Earnings Call* — Management is not signaling a full recovery.

6. **“We are prioritizing capital allocation to support operational initiatives and maintain flexibility.”**  
   *Q1 2025 Earnings Call* — Focus on liquidity and investment discipline.

7. **“FX volatility and regulatory changes on non-human primate sourcing remain key external risks.”**  
   *Q1 2025 10-Q* — Highlights potential for unexpected margin headwinds.

---

**Conclusion:**  
For Q2 2025, Charles River Laboratories is positioned for stabilization, with DSA recovery and cost controls as key levers. However, temporary DSA boosts and persistent Manufacturing headwinds warrant caution. Investors should closely monitor DSA bookings and margin trends for confirmation of a sustainable turnaround.

CRL Q2 2025: Testing DSA Recovery and Margin Stability